Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics

Sabrina Noack, Monika Raab, Yves Matthess, Mourad Sanhaji, Andrea Krämer, B. Györffy, Lars Kaderali, Ahmed El-Balat, Sven Becker, Klaus Strebhardt

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1-amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many types of cancer, which correlates with poor prognosis. Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubuletargeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism. BI6727 synergistically induces apoptosis together with paclitaxel in different cell lines including a patient-derived primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxelinduced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant loss of the mitochondrial membrane potential and activation of caspase-dependent effector pathways. This conclusion is supported by data showing that BI6727/ paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitorbased combination treatments in CCNE1-amplified HGSOC cells.

Original languageEnglish
Pages (from-to)25842-25859
Number of pages18
JournalOncotarget
Volume9
Issue number40
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Paclitaxel
Microtubules
Ovarian Neoplasms
Apoptosis
SKP Cullin F-Box Protein Ligases
Effector Caspases
Pharmaceutical Preparations
Drug Therapy
Cell Line
Taxoids
Cyclin E
Mitochondrial Membrane Potential
Therapeutics
Mitosis
Cell Division
Small Interfering RNA
Ovary
Neoplasms
Synthetic Lethal Mutations
polo-like kinase 1

Keywords

  • Cell cycle
  • Ovarian cancer
  • Paclitaxel
  • Protein kinases
  • Sensitization

ASJC Scopus subject areas

  • Oncology

Cite this

Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics. / Noack, Sabrina; Raab, Monika; Matthess, Yves; Sanhaji, Mourad; Krämer, Andrea; Györffy, B.; Kaderali, Lars; El-Balat, Ahmed; Becker, Sven; Strebhardt, Klaus.

In: Oncotarget, Vol. 9, No. 40, 01.01.2018, p. 25842-25859.

Research output: Contribution to journalArticle

Noack, S, Raab, M, Matthess, Y, Sanhaji, M, Krämer, A, Györffy, B, Kaderali, L, El-Balat, A, Becker, S & Strebhardt, K 2018, 'Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics', Oncotarget, vol. 9, no. 40, pp. 25842-25859. https://doi.org/10.18632/oncotarget.25386
Noack, Sabrina ; Raab, Monika ; Matthess, Yves ; Sanhaji, Mourad ; Krämer, Andrea ; Györffy, B. ; Kaderali, Lars ; El-Balat, Ahmed ; Becker, Sven ; Strebhardt, Klaus. / Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics. In: Oncotarget. 2018 ; Vol. 9, No. 40. pp. 25842-25859.
@article{f69a7a875b854b0bbc6b13791c2ea2d8,
title = "Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics",
abstract = "The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1-amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many types of cancer, which correlates with poor prognosis. Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubuletargeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism. BI6727 synergistically induces apoptosis together with paclitaxel in different cell lines including a patient-derived primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxelinduced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant loss of the mitochondrial membrane potential and activation of caspase-dependent effector pathways. This conclusion is supported by data showing that BI6727/ paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitorbased combination treatments in CCNE1-amplified HGSOC cells.",
keywords = "Cell cycle, Ovarian cancer, Paclitaxel, Protein kinases, Sensitization",
author = "Sabrina Noack and Monika Raab and Yves Matthess and Mourad Sanhaji and Andrea Kr{\"a}mer and B. Gy{\"o}rffy and Lars Kaderali and Ahmed El-Balat and Sven Becker and Klaus Strebhardt",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.25386",
language = "English",
volume = "9",
pages = "25842--25859",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

TY - JOUR

T1 - Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics

AU - Noack, Sabrina

AU - Raab, Monika

AU - Matthess, Yves

AU - Sanhaji, Mourad

AU - Krämer, Andrea

AU - Györffy, B.

AU - Kaderali, Lars

AU - El-Balat, Ahmed

AU - Becker, Sven

AU - Strebhardt, Klaus

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1-amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many types of cancer, which correlates with poor prognosis. Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubuletargeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism. BI6727 synergistically induces apoptosis together with paclitaxel in different cell lines including a patient-derived primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxelinduced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant loss of the mitochondrial membrane potential and activation of caspase-dependent effector pathways. This conclusion is supported by data showing that BI6727/ paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitorbased combination treatments in CCNE1-amplified HGSOC cells.

AB - The taxanes are effective microtubule-stabilizing chemotherapy drugs that inhibit mitosis, induce apoptosis, and produce regression in a fraction of cancers that arise at many sites including the ovary. Novel therapeutic targets that augment taxane effects are needed to improve clinical chemotherapy response in CCNE1-amplified high grade serous ovarian cancer (HGSOC) cells. In this study, we conducted an siRNA-based kinome screen to identify modulators of mitotic progression in CCNE1-amplified HGSOC cells that may influence clinical paclitaxel response. PLK1 is overexpressed in many types of cancer, which correlates with poor prognosis. Here, we identified a novel synthetic lethal interaction of the clinical PLK1 inhibitor BI6727 and the microtubuletargeting drug paclitaxel in HGSOC cell lines with CCNE1-amplification and elucidated the underlying molecular mechanisms of this synergism. BI6727 synergistically induces apoptosis together with paclitaxel in different cell lines including a patient-derived primary ovarian cancer culture. Moreover, the inhibition of PLK1 reduced the paclitaxelinduced neurotoxicity in a neurite outgrowth assay. Mechanistically, the combinatorial treatment with BI6727/paclitaxel triggers mitotic arrest, which initiates mitochondrial apoptosis by inactivation of anti-apoptotic BCL-2 family proteins, followed by significant loss of the mitochondrial membrane potential and activation of caspase-dependent effector pathways. This conclusion is supported by data showing that BI6727/ paclitaxel-co-treatment stabilizes FBW7, a component of SCF-type ubiquitin ligases that bind and regulate key modulators of cell division and growth including MCL-1 and Cyclin E. This identification of a novel synthetic lethality of PLK1 inhibitors and a microtubule-stabilizing drug has important implications for developing PLK1 inhibitorbased combination treatments in CCNE1-amplified HGSOC cells.

KW - Cell cycle

KW - Ovarian cancer

KW - Paclitaxel

KW - Protein kinases

KW - Sensitization

UR - http://www.scopus.com/inward/record.url?scp=85047469060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047469060&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25386

DO - 10.18632/oncotarget.25386

M3 - Article

AN - SCOPUS:85047469060

VL - 9

SP - 25842

EP - 25859

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -